Patient features for HIV-Ly and control-Ly cohorts
| Feature . | HIV-Ly cohort . | Control-Ly cohort . | P . | ||
|---|---|---|---|---|---|
| n . | % . | n . | % . | ||
| Patients | 53 | 100 | 53 | 100 | NS |
| Median age, y (range) | 40.7 (29-62.5) | 44.3 (19.5-64) | NS | ||
| Male sex | 43 | 81 | 33 | 62 | .05 |
| Non-Hodgkin lymphoma | 35 | 66 | 35 | 66 | NS |
| Diffuse large B-cell/plasmablastic | 28 | 80 | 28 | 80 | NS |
| Burkitt/Burkitt-like | 3 | 8.5 | 3 | 8.5 | NS |
| Peripheral T-cell | 4 | 11.5 | 4 | 11.5 | NS |
| IPI at diagnosis > 2 (except Burkitt) | 18 | 62 | 21 | 65.5 | NS |
| Hodgkin lymphoma | 18 | 34 | 18 | 34 | NS |
| Mixed cellularity | 8 | 61.5 | 3 | 17.5 | .01 |
| Nodular sclerosis | 3 | 23 | 11 | 65 | .03 |
| Ann Arbor stage at diagnosis > II | 11 | 61 | 11 | 61 | NS |
| Treatment before ASCT | |||||
| Median no. of treatment lines (range) | 2 (1-5) | 2 (1-4) | NS | ||
| Patients undergoing rituximab treatment | 18 | 35.6 | 22 | 41.5 | NS |
| Disease status at ASCT | |||||
| Complete remission | 25 | 47 | 25 | 47 | NS |
| First complete remission | 12 | 22.5 | 12 | 22.5 | |
| Partial remission/chemosensitive relapse | 10/13 | 19/24.5 | 13/10 | 24.5/19 | NS |
| Primary induction failure/chemoresistant relapse | 5 | 9.5 | 5 | 9.5 | NS |
| Conditioning regimen | |||||
| TBI-based regimens | 3 | 5.5 | 6 | 11.5 | .04 |
| BEAM/variants | 50 | 94.5 | 43 | 81 | NS |
| Other conditioning schemes | 0 | 0 | 4 | 7.5 | NS |
| Median CD34+ infused cells × 106/kg (range) | 5.1 (1.6-21) | 3.9 (0.9-17) | NS | ||
| Patients on G-CSF before engraftment | 47 | 89 | 31 | 58.5 | .001 |
| Post-ASCT antitumor preemptive treatment | 9 | 17 | 6 | 11 | NS |
| Local radiotherapy | 8 | 15 | 4 | 7.5 | NS |
| Rituximab | 1 | 2 | 2 | 3.5 | NS |
| Median months of follow-up from ASCT (range) | 30 (3-81) | 29.5 (3-98) | NS | ||
| Median months to ASCT from diagnosis (range) | 14.5 (4.5-106) | 17 (4-173) | NS | ||
| Patients with follow-up censored at second ASCT | 1 | 2 | 5 | 9.5 | NS |
| Feature . | HIV-Ly cohort . | Control-Ly cohort . | P . | ||
|---|---|---|---|---|---|
| n . | % . | n . | % . | ||
| Patients | 53 | 100 | 53 | 100 | NS |
| Median age, y (range) | 40.7 (29-62.5) | 44.3 (19.5-64) | NS | ||
| Male sex | 43 | 81 | 33 | 62 | .05 |
| Non-Hodgkin lymphoma | 35 | 66 | 35 | 66 | NS |
| Diffuse large B-cell/plasmablastic | 28 | 80 | 28 | 80 | NS |
| Burkitt/Burkitt-like | 3 | 8.5 | 3 | 8.5 | NS |
| Peripheral T-cell | 4 | 11.5 | 4 | 11.5 | NS |
| IPI at diagnosis > 2 (except Burkitt) | 18 | 62 | 21 | 65.5 | NS |
| Hodgkin lymphoma | 18 | 34 | 18 | 34 | NS |
| Mixed cellularity | 8 | 61.5 | 3 | 17.5 | .01 |
| Nodular sclerosis | 3 | 23 | 11 | 65 | .03 |
| Ann Arbor stage at diagnosis > II | 11 | 61 | 11 | 61 | NS |
| Treatment before ASCT | |||||
| Median no. of treatment lines (range) | 2 (1-5) | 2 (1-4) | NS | ||
| Patients undergoing rituximab treatment | 18 | 35.6 | 22 | 41.5 | NS |
| Disease status at ASCT | |||||
| Complete remission | 25 | 47 | 25 | 47 | NS |
| First complete remission | 12 | 22.5 | 12 | 22.5 | |
| Partial remission/chemosensitive relapse | 10/13 | 19/24.5 | 13/10 | 24.5/19 | NS |
| Primary induction failure/chemoresistant relapse | 5 | 9.5 | 5 | 9.5 | NS |
| Conditioning regimen | |||||
| TBI-based regimens | 3 | 5.5 | 6 | 11.5 | .04 |
| BEAM/variants | 50 | 94.5 | 43 | 81 | NS |
| Other conditioning schemes | 0 | 0 | 4 | 7.5 | NS |
| Median CD34+ infused cells × 106/kg (range) | 5.1 (1.6-21) | 3.9 (0.9-17) | NS | ||
| Patients on G-CSF before engraftment | 47 | 89 | 31 | 58.5 | .001 |
| Post-ASCT antitumor preemptive treatment | 9 | 17 | 6 | 11 | NS |
| Local radiotherapy | 8 | 15 | 4 | 7.5 | NS |
| Rituximab | 1 | 2 | 2 | 3.5 | NS |
| Median months of follow-up from ASCT (range) | 30 (3-81) | 29.5 (3-98) | NS | ||
| Median months to ASCT from diagnosis (range) | 14.5 (4.5-106) | 17 (4-173) | NS | ||
| Patients with follow-up censored at second ASCT | 1 | 2 | 5 | 9.5 | NS |
HIV-Ly indicates cohort of AIDS-related lymphoma patients treated with autologous peripheral blood stem cell transplantation (ASCT); Control-Ly, matched cohort of HIV-negative lymphoma patients treated with ASCT; NS, not significant; TBI, total body irradiation; and BEAM, BCNU, etoposide, Ara-C, melphalan.